Agonists at PPAR‐γ suppress angiotensin II‐induced production of plasminogen activator inhibitor‐1 and extracellular matrix in rat cardiac fibroblasts
Authors:
- 1 April 2008
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 153 (7) , 1409-1419
Abstract
Background and purpose: Peroxisome proliferator‐activated receptor (PPAR)‐γ ligands have been shown to inhibit cardiac fibrosis. However, the underlying mechanisms are poorly understood. We investigated the regulation by PPAR‐γ ligands of angiotensin (Ang) II‐induced plasminogen activator inhibitor (PAI)‐1, extracellular matrix (ECM) production and cell growth in cardiac fibroblasts.Experimental approach: The effects of PPAR‐γ ligands on Ang II‐induced PAI‐1, ECM expression and cell growth were assessed in primary‐cultured rat cardiac fibroblasts; cardiac PAI‐1 and ECM production was examined in Ang II‐infused rats.Key results: In growth‐arrested cardiac fibroblasts, PPAR‐γ ligands rosiglitazone and 15‐deoxy‐Δ12,14‐prostaglandin J2 (15d‐PGJ2) dose‐dependently attenuated Ang II‐induced cell proliferation and expression of PAI‐1, collagen type‐I, collagen type‐III and fibronectin. An accompanying increase in PPAR‐γ expression and activation was also observed. These suppressive effects were attenuated by the PPAR‐γ antagonists GW9662 and bisphenol A diglycidyl ether (BADGE). Moreover, rosiglitazone and 15d‐PGJ2 inhibited in part the expression and phosphorylation of Ang II‐induced transforming growth factor (TGF)‐β1, Smad2/3 and c‐Jun NH(2)‐terminal kinase (JNK). Ang II infusion in rats markedly increased left ventricular production of PAI‐1, collagen and fibronectin, with a concurrent increase in the ratios of heart weight/body weight and left ventricle weight/body weight. Co‐treatment with rosiglitazone significantly decreased these levels and upregulated PPAR‐γ expression.Conclusions and implications: Rosiglitazone and 15d‐PGJ2 suppress Ang II‐induced production of PAI‐1 and ECM probably via interactions between PPAR‐γ and TGF‐β1/Smad2/3 and JNK signalling pathways. It is suggested that PPAR‐γ and its ligands may have potential applications in preventing cardiac fibrosis.British Journal of Pharmacology (2008) 153, 1409–1419; doi:10.1038/bjp.2008.21; published online 18 February 2008Keywords
This publication has 52 references indexed in Scilit:
- PPARγ agonists prevent TGFβ1/Smad3-signaling in human hepatic stellate cellsBiochemical and Biophysical Research Communications, 2006
- Effect of peroxisome proliferator-activated receptor γ ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarctionInternational Journal of Cardiology, 2006
- PPARγ agonists exert antifibrotic effects in renal tubular cells exposed to high glucoseAmerican Journal of Physiology-Renal Physiology, 2005
- Pharmacological Inhibition and Genetic Deficiency of Plasminogen Activator Inhibitor-1 Attenuates Angiotensin II/Salt-Induced Aortic RemodelingArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Angiotensin II Regulation of Collagen Type I Expression in Cardiac FibroblastsHypertension, 2004
- Peroxisome Proliferator-Activated Receptor γ: Implications for Cardiovascular DiseaseHypertension, 2004
- Peroxisome Proliferator-Activated Receptor-α and Receptor-γ Activators Prevent Cardiac Fibrosis in Mineralocorticoid-Dependent HypertensionHypertension, 2003
- Expression and Function of Peroxisome Proliferator–Activated Receptor-γ in Mesangial CellsHypertension, 2001
- Thiazolidinediones Down-Regulate Plasminogen Activator Inhibitor Type 1 Expression in Human Vascular Endothelial Cells: A Possible Role for PPARγ in Endothelial FunctionBiochemical and Biophysical Research Communications, 1999
- Angiotensin II Induces Cardiac Phenotypic Modulation and Remodeling In Vivo in RatsHypertension, 1995